Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H1 2017

  • ID: 4315549
  • Report
  • 71 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Domainex Ltd
  • EpiZyme Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Pfizer Inc
  • Transgene Biotek Ltd
  • MORE
Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H1 2017

Summary:

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The latest report Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2017, outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 6 respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Follicular Lymphoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Chondrosarcoma, Epithelial Tumor, Hematological Tumor, Lung Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Metastatic Liver Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma and T-Cell Leukemia.

Furthermore, this report also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
  • The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Domainex Ltd
  • EpiZyme Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Pfizer Inc
  • Transgene Biotek Ltd
  • MORE
  1. Introduction
  2. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview
  3. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development
  4. Products under Development by Stage of Development
  5. Products under Development by Therapy Area
  6. Products under Development by Indication
  7. Products under Development by Companies
  8. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
  13. Daiichi Sankyo Company Ltd
  14. Domainex Ltd
  15. EpiZyme Inc
  16. GlaxoSmithKline Plc
  17. Kainos Medicine Inc
  18. Pfizer Inc
  19. Transgene Biotek Ltd
  20. UNC Health Care
  21. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles
  22. CPI-1205 - Drug Profile
  23. Product Description
  24. Mechanism Of Action
  25. R&D Progress
  26. CPI-169 - Drug Profile
  27. Product Description
  28. Mechanism Of Action
  29. R&D Progress
  30. DS-3201 - Drug Profile
  31. Product Description
  32. Mechanism Of Action
  33. R&D Progress
  34. EBI-2554 - Drug Profile
  35. Product Description
  36. Mechanism Of Action
  37. R&D Progress
  38. GSK-2816126 - Drug Profile
  39. Product Description
  40. Mechanism Of Action
  41. R&D Progress
  42. GSK-343 - Drug Profile
  43. Product Description
  44. Mechanism Of Action
  45. R&D Progress
  46. JQEZ-5 - Drug Profile
  47. Product Description
  48. Mechanism Of Action
  49. R&D Progress
  50. KM-301 - Drug Profile
  51. Product Description
  52. Mechanism Of Action
  53. R&D Progress
  54. ORS-1 - Drug Profile
  55. Product Description
  56. Mechanism Of Action
  57. R&D Progress
  58. Small Molecule to Inhibit EZH2 for Oncology - Drug Profile
  59. Product Description
  60. Mechanism Of Action
  61. R&D Progress
  62. Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
  63. Product Description
  64. Mechanism Of Action
  65. R&D Progress
  66. Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
  67. Product Description
  68. Mechanism Of Action
  69. R&D Progress
  70. Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile
  71. Product Description
  72. Mechanism Of Action
  73. R&D Progress
  74. tazemetostat - Drug Profile
  75. Product Description
  76. Mechanism Of Action
  77. R&D Progress
  78. TBL-0404 - Drug Profile
  79. Product Description
  80. Mechanism Of Action
  81. R&D Progress
  82. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products
  83. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products
  84. Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones
  85. Featured News & Press Releases
  86. May 18, 2017: Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO
  87. Apr 25, 2017: Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
  88. Apr 20, 2017: Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
  89. Nov 28, 2016: Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update
  90. Aug 11, 2016: Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma
  91. Jun 19, 2016: Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
  92. May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology
  93. May 04, 2016: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma
  94. May 03, 2016: New investigational compound shows promise against melanoma, lymphoma
  95. Apr 18, 2016: Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting
  96. Mar 17, 2016: Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program
  97. Mar 09, 2016: Epizyme Unveils Corporate Strategy to Guide Efforts over Next Five Years
  98. Feb 08, 2016: Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA
  99. Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors
  100. Dec 28, 2015: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Diffuse Large B-cell Lymphoma
  101. Appendix
  102. Methodology
  103. Coverage
  104. Secondary Research
  105. Primary Research
  106. Expert Panel Validation
  107. Contact Us
  108. Disclaimer
List of Tables:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Indications, H1
  4. Number of Products under Development by Indications, H1 2017 (Contd..1), H1
  5. Number of Products under Development by Companies, H1
  6. Products under Development by Companies, H1
  7. Products under Development by Companies, H1 2017 (Contd..1), H1
  8. Products under Development by Companies, H1 2017 (Contd..2), H1
  9. Number of Products by Stage and Mechanism of Actions, H1
  10. Number of Products by Stage and Route of Administration, H1
  11. Number of Products by Stage and Molecule Type, H1
  12. Pipeline by Daiichi Sankyo Company Ltd, H1
  13. Pipeline by Domainex Ltd, H1
  14. Pipeline by EpiZyme Inc, H1
  15. Pipeline by GlaxoSmithKline Plc, H1
  16. Pipeline by Kainos Medicine Inc, H1
  17. Pipeline by Pfizer Inc, H1
  18. Pipeline by Transgene Biotek Ltd, H1
  19. Pipeline by UNC Health Care, H1
  20. Dormant Projects, H1
  21. Discontinued Products, H1
List of Figures:
  1. Number of Products under Development by Stage of Development, H1
  2. Number of Products under Development by Therapy Areas, H1
  3. Number of Products under Development by Top 10 Indications, H1
  4. Number of Products by Stage and Mechanism of Actions, H1
  5. Number of Products by Routes of Administration, H1
  6. Number of Products by Stage and Routes of Administration, H1
  7. Number of Products by Molecule Types, H1
  8. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Daiichi Sankyo Company Ltd
  • Domainex Ltd
  • EpiZyme Inc
  • GlaxoSmithKline Plc
  • Kainos Medicine Inc
  • Pfizer Inc
  • Transgene Biotek Ltd
  • UNC Health Care
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll